Hims & Hers Health (NYSE:HIMS) Receives New Coverage from Analysts at Guggenheim

Investment analysts at Guggenheim began coverage on shares of Hims & Hers Health (NYSE:HIMSGet Rating) in a research note issued on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock.

Several other brokerages have also recently commented on HIMS. Citigroup dropped their target price on shares of Hims & Hers Health from $14.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, December 20th. Zacks Investment Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Friday, February 25th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Hims & Hers Health in a research report on Thursday, March 10th. They issued a “hold” rating and a $7.00 price objective for the company. Finally, Piper Sandler lowered their price objective on shares of Hims & Hers Health from $12.00 to $8.00 in a research report on Wednesday, February 23rd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Buy” and a consensus target price of $11.00.

NYSE:HIMS traded up $0.13 during trading hours on Wednesday, hitting $5.02. 1,688,813 shares of the stock were exchanged, compared to its average volume of 2,334,174. The company’s 50 day moving average is $4.86 and its two-hundred day moving average is $6.05. Hims & Hers Health has a twelve month low of $3.86 and a twelve month high of $15.55. The company has a market capitalization of $1.03 billion, a P/E ratio of -8.10 and a beta of 0.18.

Hims & Hers Health (NYSE:HIMSGet Rating) last issued its earnings results on Tuesday, February 22nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The business had revenue of $84.70 million for the quarter, compared to the consensus estimate of $76.79 million. Hims & Hers Health had a negative net margin of 39.60% and a negative return on equity of 24.28%. The business’s revenue was up 104.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.07) EPS. On average, research analysts anticipate that Hims & Hers Health will post -0.24 earnings per share for the current fiscal year.

In other news, Director Lynne Chou O’keefe sold 10,044 shares of the stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $4.50, for a total transaction of $45,198.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 24,516 shares of the stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $4.41, for a total transaction of $108,115.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 145,896 shares of company stock valued at $714,701. Company insiders own 43.70% of the company’s stock.

A number of large investors have recently modified their holdings of HIMS. Dark Forest Capital Management LP acquired a new stake in Hims & Hers Health in the 3rd quarter valued at about $32,000. Advisor Group Holdings Inc. lifted its stake in Hims & Hers Health by 77.4% in the 3rd quarter. Advisor Group Holdings Inc. now owns 6,926 shares of the company’s stock valued at $51,000 after purchasing an additional 3,021 shares during the last quarter. Bradley Foster & Sargent Inc. CT acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $65,000. NorthRock Partners LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $67,000. Finally, Versor Investments LP acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $67,000. Institutional investors and hedge funds own 43.89% of the company’s stock.

About Hims & Hers Health (Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

See Also

The Fly logo

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.